Browse SYTL2

Summary
SymbolSYTL2
Namesynaptotagmin-like 2
Aliases FLJ20163; FLJ21219; KIAA1597; exophilin-4; CHR11SYT; SLP2; SGA72M; MGC102768; PPP1R151; chromosome 11 synapt ......
Chromosomal Location11q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Cytoplasm Cell membrane Note=Recruited on vesicular structures in cytotoxic T-lymphocytes (CTL) by RAB27A. ; SUBCELLULAR LOCATION: Isoform 4: Cell membrane Note=In the pancreatic alpha cells distributed in both peripheral and anterior regions. Localizes on the glucagon granules in the cell periphery.
Domain PF00168 C2 domain
Function

Isoform 1 acts as a RAB27A effector protein and plays a role in cytotoxic granule exocytosis in lymphocytes. It is required for cytotoxic granule docking at the immunologic synapse. Isoform 4 binds phosphatidylserine (PS) and phosphatidylinositol-4,5-bisphosphate (PIP2) and promotes the recruitment of glucagon-containing granules to the cell membrane in pancreatic alpha cells. Binding to PS is inhibited by Ca(2+) while binding to PIP2 is Ca(2+) insensitive.

> Gene Ontology
 
Biological Process GO:0006887 exocytosis
GO:0006904 vesicle docking involved in exocytosis
GO:0006906 vesicle fusion
GO:0007009 plasma membrane organization
GO:0007589 body fluid secretion
GO:0010921 regulation of phosphatase activity
GO:0010923 negative regulation of phosphatase activity
GO:0016050 vesicle organization
GO:0016311 dephosphorylation
GO:0022406 membrane docking
GO:0032941 secretion by tissue
GO:0035303 regulation of dephosphorylation
GO:0035305 negative regulation of dephosphorylation
GO:0044801 single-organism membrane fusion
GO:0048278 vesicle docking
GO:0048284 organelle fusion
GO:0050878 regulation of body fluid levels
GO:0051047 positive regulation of secretion
GO:0051346 negative regulation of hydrolase activity
GO:0061025 membrane fusion
GO:0070254 mucus secretion
GO:0070255 regulation of mucus secretion
GO:0070257 positive regulation of mucus secretion
GO:0072657 protein localization to membrane
GO:0072659 protein localization to plasma membrane
GO:0090174 organelle membrane fusion
GO:1990778 protein localization to cell periphery
Molecular Function GO:0000149 SNARE binding
GO:0001786 phosphatidylserine binding
GO:0005543 phospholipid binding
GO:0005544 calcium-dependent phospholipid binding
GO:0005546 phosphatidylinositol-4,5-bisphosphate binding
GO:0017016 Ras GTPase binding
GO:0017137 Rab GTPase binding
GO:0019902 phosphatase binding
GO:0019905 syntaxin binding
GO:0030276 clathrin binding
GO:0031267 small GTPase binding
GO:0035091 phosphatidylinositol binding
GO:0042043 neurexin family protein binding
GO:0051020 GTPase binding
GO:0072341 modified amino acid binding
GO:1901981 phosphatidylinositol phosphate binding
GO:1902936 phosphatidylinositol bisphosphate binding
Cellular Component GO:0019897 extrinsic component of plasma membrane
GO:0019898 extrinsic component of membrane
GO:0030133 transport vesicle
GO:0042470 melanosome
GO:0048770 pigment granule
GO:0070382 exocytic vesicle
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolSYTL2
Namesynaptotagmin-like 2
Aliases FLJ20163; FLJ21219; KIAA1597; exophilin-4; CHR11SYT; SLP2; SGA72M; MGC102768; PPP1R151; chromosome 11 synapt ......
Chromosomal Location11q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SYTL2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSYTL2
Namesynaptotagmin-like 2
Aliases FLJ20163; FLJ21219; KIAA1597; exophilin-4; CHR11SYT; SLP2; SGA72M; MGC102768; PPP1R151; chromosome 11 synapt ......
Chromosomal Location11q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SYTL2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.65 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSYTL2
Namesynaptotagmin-like 2
Aliases FLJ20163; FLJ21219; KIAA1597; exophilin-4; CHR11SYT; SLP2; SGA72M; MGC102768; PPP1R151; chromosome 11 synapt ......
Chromosomal Location11q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SYTL2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2450.648
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2060.9
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5680.629
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0970.837
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.470.849
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7980.77
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1070.803
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.620.686
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.4730.783
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1460.937
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0440.987
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0290.856
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SYTL2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 1417011.8-11.80.488
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103066.7-66.70.0385
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277318.55.5130.0572
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275918.55.113.40.102
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.112.5-1.41
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSYTL2
Namesynaptotagmin-like 2
Aliases FLJ20163; FLJ21219; KIAA1597; exophilin-4; CHR11SYT; SLP2; SGA72M; MGC102768; PPP1R151; chromosome 11 synapt ......
Chromosomal Location11q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SYTL2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSYTL2
Namesynaptotagmin-like 2
Aliases FLJ20163; FLJ21219; KIAA1597; exophilin-4; CHR11SYT; SLP2; SGA72M; MGC102768; PPP1R151; chromosome 11 synapt ......
Chromosomal Location11q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SYTL2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SYTL2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSYTL2
Namesynaptotagmin-like 2
Aliases FLJ20163; FLJ21219; KIAA1597; exophilin-4; CHR11SYT; SLP2; SGA72M; MGC102768; PPP1R151; chromosome 11 synapt ......
Chromosomal Location11q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SYTL2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSYTL2
Namesynaptotagmin-like 2
Aliases FLJ20163; FLJ21219; KIAA1597; exophilin-4; CHR11SYT; SLP2; SGA72M; MGC102768; PPP1R151; chromosome 11 synapt ......
Chromosomal Location11q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SYTL2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSYTL2
Namesynaptotagmin-like 2
Aliases FLJ20163; FLJ21219; KIAA1597; exophilin-4; CHR11SYT; SLP2; SGA72M; MGC102768; PPP1R151; chromosome 11 synapt ......
Chromosomal Location11q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SYTL2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSYTL2
Namesynaptotagmin-like 2
Aliases FLJ20163; FLJ21219; KIAA1597; exophilin-4; CHR11SYT; SLP2; SGA72M; MGC102768; PPP1R151; chromosome 11 synapt ......
Chromosomal Location11q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SYTL2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.